Findings showed 42.9% of P1101-treated patients achieved durable responses at both 9 and 12 months compared with 6% in those treated with anagrelide (P =.0001). Topline data were announced from a ...
With phase 3 trial win, PharmaEssentia plots label expansion for rare blood cancer treatment Besremi
In the SURPASS-ET trial, the company weighed its treatment, dubbed P1101 in the study, against platelet-reducing anagrelide as a second-line therapy for patients with essential thrombocythemia (ET).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback